Estrogen Receptor- And Progesterone Receptor-Positive Thresholds in Predicting the Recurrence of Early Low-Risk Endometrial Cancer

被引:0
作者
Li, Ning [1 ,2 ]
Jiang, Peng [1 ]
Huang, Yuzhen [1 ]
Tu, Yuan [1 ]
Kong, Wei [1 ]
Jiang, Shan [1 ]
Zhang, Jingni [1 ]
Wu, Yijun [2 ]
Zhang, Xiaorong [2 ]
Xie, Qingning [2 ]
Yuan, Rui [1 ,3 ]
机构
[1] Chongqing Med Univ, Affiliated Hosp 1, Dept Gynecol, Chongqing, Peoples R China
[2] Peoples Hosp Shapingba Dist, Dept Gynecol, Chongqing, Peoples R China
[3] Chongqing Med Univ, Affiliated Hosp 1, Dept Gynecol, 1 Med Coll Rd, Chongqing 400016, Peoples R China
关键词
Estrogen receptor; progesterone receptor; positive threshold; early low-risk endometrial cancer; recurrence;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background:Estrogen receptors (ER) and progesterone receptors (PR) have important prognostic value in endometrial cancer, but there is no recognized positive immunohistochemical threshold for predicting the recurrence of early low-risk endometrial cancer. The purpose of this study was to clarify the optimal positive thresholds of the immunohistochemical parameters the ER and PR in early low-risk endometrial cancer. Methods:A total of 332 patients with stage IA endometrial cancer were enrolled from the First Affiliated Hospital of Chongqing Medical University and People's Hospital of Sha ping ba District in Chongqing between January 2013 and December 2018. First, univariate and multivariate Cox regression analyses were used to analyze the correlation between various clinical factors and the prognosis of early low-risk endometrial cancer. Then, the receiver operating characteristic curve (ROC curve) and Youden index were used to determine the positive thresholds of ER and PR. Results:The positive thresholds of ER and PR for predicting the recurrence of early low-risk endometrial cancer were 12% and 8%, respectively. Multivariate analysis showed that ER (P = 0.004), PR (P = 0.026), and p53 (P = 0.021) were risk factors for the prognosis of patients with early low-risk endometrial cancer. The recurrence-free survival and the overall survival in the low ER group and PR group were much lower than those in the high ER group and PR group (P < 0.001 of all). Conclusions:ER and PR positive thresholds of 12% and 8%, respectively, are the most suitable for predicting the recurrence of early low-risk endometrial cancer.
引用
收藏
页数:9
相关论文
共 34 条
[1]   Refining the Definition of Low-Risk Endometrial Cancer: Improving Value [J].
Bakkum-Gamez, Jamie N. .
GYNECOLOGIC ONCOLOGY, 2016, 141 (02) :189-190
[2]   Histological and immunohistochemical profiles predict lymph node status in women with low-intermediate risk endometrial cancer [J].
Ballester, Marcos ;
Canlorbe, Geoffroy ;
Cortez, Annie ;
Gonin, Julie ;
Laas, Enora ;
Bendifallah, Sofiane ;
Graesslin, Olivier ;
Darai, Emile .
GYNECOLOGIC ONCOLOGY, 2013, 130 (03) :457-462
[3]   Temporal pattern of recurrence of stage I endometrial cancer in relation to histological risk factors [J].
Ben Arie, A. ;
Lavie, O. ;
Gdalevich, M. ;
Voldarsky, M. ;
Barak, F. ;
Schneider, D. ;
Levy, T. ;
Anteby, E. ;
Gemer, O. .
EJSO, 2012, 38 (02) :166-169
[4]   Patterns of recurrence and outcomes in surgically treated women with endometrial cancer according to ESMO-ESGO-ESTRO Consensus Conference risk groups: Results from the FRANCOGYN study Group [J].
Bendifallah, Sofiane ;
Ouldamer, Lobna ;
Lavoue, Vincent ;
Canlorbe, Geoffroy ;
Raimond, Emilie ;
Coutant, Charles ;
Graesslin, Olivier ;
Touboul, Cyril ;
Collinet, Pierre ;
Darai, Emile ;
Ballester, Marcos .
GYNECOLOGIC ONCOLOGY, 2017, 144 (01) :107-112
[5]   Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials): pooled trial results,, systematic review, and meta-analysis [J].
Blake, P. ;
Swart, Ann Marie ;
Orton, J. ;
Kitchener, H. ;
Whelan, T. ;
Lukka, H. ;
Eisenhauer, E. ;
Bacon, M. ;
Tu, D. ;
Parmar, M. K. B. ;
Amos, C. ;
Murray, C. ;
Qian, W. .
LANCET, 2009, 373 (9658) :137-146
[6]   Tumor Size, an Additional Prognostic Factor to Include in Low-Risk Endometrial Cancer: Results of a French Multicenter Study [J].
Canlorbe, Geoffroy ;
Bendifallah, Sofiane ;
Laas, Enora ;
Raimond, Emilie ;
Graesslin, Olivier ;
Hudry, Delphine ;
Coutant, Charles ;
Touboul, Cyril ;
Bleu, Geraldine ;
Collinet, Pierre ;
Cortez, Annie ;
Darai, Emile ;
Ballester, Marcos .
ANNALS OF SURGICAL ONCOLOGY, 2016, 23 (01) :171-177
[7]   Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up [J].
Colombo, N. ;
Preti, E. ;
Landoni, F. ;
Carinelli, S. ;
Colombo, A. ;
Marini, C. ;
Sessa, C. .
ANNALS OF ONCOLOGY, 2013, 24 :33-38
[8]   Can the Determination of HE4 and CA125 Markers Affect the Treatment of Patients with Endometrial Cancer? [J].
Cymbaluk-Ploska, Aneta ;
Gargulinska, Paula ;
Bulsa, Michal ;
Kwiatkowski, Sebastian ;
Chudecka-Glaz, Anita ;
Michalczyk, Kaja .
DIAGNOSTICS, 2021, 11 (04)
[9]   Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial [J].
de Boer, Stephanie M. ;
Powell, Melanie E. ;
Mileshkin, Linda ;
Katsaros, Dionyssios ;
Bessette, Paul ;
Haie-Meder, Christine ;
Ottevanger, Petronella B. ;
Ledermann, Jonathan A. ;
Khaw, Pearly ;
Colombo, Alessandro ;
Fyles, Anthony ;
Baron, Marie-Helene ;
Jurgenliemk-Schulz, Ina M. ;
Kitchener, Henry C. ;
Nijman, Hans W. ;
Wilson, Godfrey ;
Brooks, Susan ;
Carinelli, Silvestro ;
Provencher, Diane ;
Hanzen, Chantal ;
Lutgens, Ludy C. H. W. ;
Smit, Vincent T. H. B. M. ;
Singh, Naveena ;
Do, Viet ;
D'Amico, Romerai ;
Nout, Remi A. ;
Feeney, Amanda ;
Verhoeven-Adema, Karen W. ;
Putter, Hein ;
Creutzberg, Carien L. .
LANCET ONCOLOGY, 2018, 19 (03) :295-309
[10]   Progesterone action in breast, uterine, and ovarian cancers [J].
Diep, Caroline H. ;
Daniel, Andrea R. ;
Mauro, Laura J. ;
Knutson, Todd P. ;
Lange, Carol A. .
JOURNAL OF MOLECULAR ENDOCRINOLOGY, 2015, 54 (02) :R31-R53